Welcure Drugs & Pharmaceutical

BSE: WELCURE · Pharmaceuticals · sector

₹0.18BSE close 2026-10-26

Key numbers

Market cap₹2 cr

Price₹0.18

52w high / low₹1 / ₹0

P/E0.1xSector median 27.9x

P/B0.0xSector median 2.9x

Book value₹8.6

Dividend yield–Sector median 0.48%

ROE-17.0%Sector median 11.7%

ROCE-6.1%Sector median 12.3%

OPM-2.0%Sector median 14.0%

Debt / equity0.00xSector median 0.16x

EV/EBITDA–Sector median 18.6x

Interest cover–

Current ratio1.67x

Sales growth 3y–Sector median +9.6%

Profit growth 3y–Sector median +13.3%

PEG–

Last 12 months to Mar 2026, Standalone. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.

Things to know

Cash ₹1 cr vs borrowings ₹0 cr (FY26): cash is higher (net cash).
Net loss in 1 of the last 5 quarters.
No dividend in the last 5 financial years.
Price ₹0.18 on 2026-10-26: -75.0% from the 52-week high, 0.0% from the 52-week low.

Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.

Charts

Weekly close · high ₹0.74 · low ₹0.18

Quarterly results

₹ cr	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	21	300	66	0	0
EBITDA	1	31	11	-0	-50
OPM %	3.0%	10.4%	17.3%	–	–
Other income	2	0	0	1	0
Net profit	3	23	8	1	-50
EPS (₹)	0.33	2.07	0.76	0.13	0.40
Revenue YoY					-100.0%
Profit YoY					-2,063.0%

Standalone figures where filed. Latest quarter Mar 2026.

Profit & loss (yearly)

₹ cr	FY22	FY23	FY24	FY25	FY26	TTM
Revenue	0	–	–	25	366	366
EBITDA	0	-0	-0	1	-7	-7
Net profit	0	0	-0	2	-5	-17
EPS (₹)	0.02	–	-0.13	0.36	0.04	3.36
Revenue growth		–	–	–	+1,389.0%	–
Profit growth		+400.0%	-280.0%	–	-353.0%	–
Dividend / share (₹)	–	–	–	–	–

Compounded growth	3 years	5 years	Last 12 months
Sales	–	–	–
Net profit	–	–	–
EPS	–	–	–
Share price	–	-83.9% (2y)	-73.0%

Balance sheet

₹ cr	FY25	FY26
Shareholders' equity	103	97
Borrowings	123	0
Cash & equivalents	0	1
Total assets	267	510
Fixed assets	0	0
Investments	0	0
Receivables	19	213
Inventory	144	144
Payables	3	0

Year-end figures from the March annual filing.

Cash flow

₹ cr	FY25	FY26
Cash from operations	-222	2
Cash from investing	-0	-1
Cash from financing	222	0
Capex	0	0
Free cash flow	-222	2

Free cash flow = cash from operations − capex.

Ratios by year

₹ cr	FY25	FY26
ROE %	2.1%	-5.7%
ROCE %	1.2%	-5.7%
Debtor days	282	213
Inventory days	2,555	163
Payable days	52	0
Cash conversion cycle (days)	2,785	376
Working capital days	2,094	144

Peers in Pharmaceuticals

Company	Market cap	P/E	P/B	ROE	ROCE	OPM	Sales 3y	Div yield
SUNPHARMA	₹4,17,478 cr	34.5x	5.0x	15.5%	18.7%	28.6%	+10.0%	0.94%
DIVISLAB	₹2,39,825 cr	82.1x	14.3x	18.4%	23.0%	34.7%	+10.8%	0.34%
TORNTPHARM	₹1,53,999 cr	72.7x	18.4x	27.3%	15.1%	32.3%	+13.3%	0.84%
ZYDUSLIFE	₹1,15,808 cr	25.9x	4.3x	17.7%	16.8%	27.2%	+16.4%	0.95%
LAURUSLABS	₹1,11,232 cr	101.6x	21.0x	22.4%	20.8%	28.0%	+4.1%	0.08%
CIPLA	₹1,09,464 cr	32.5x	3.2x	10.3%	13.2%	17.7%	+7.4%	1.18%
DRREDDY	₹1,09,460 cr	33.9x	2.9x	9.0%	10.1%	15.5%	+11.0%	0.61%
MANKIND	₹95,486 cr	46.7x	5.9x	13.4%	13.8%	25.1%	+17.7%	0.04%
AUROPHARMA	₹91,489 cr	24.9x	2.4x	10.5%	12.8%	20.0%	+10.6%	0.26%
WELCURE	₹2 cr	0.1x	0.0x	-17.0%	-6.1%	-2.0%	–	–

All 185 companies in Pharmaceuticals →

Business segments (2026-03-31)

Segment	Revenue	Share	EBIT	Margin
Agriculture	₹0 cr	–	₹-50 cr	–
Drugs and Pharmaceuticals	₹0 cr	–	₹0 cr	–

Documents

Links go to the original files on the exchange website.

About the company


Sector	Healthcare
Industry	Pharmaceuticals
Sub-industry	Pharmaceuticals
Symbol	WELCURE
BSE code	524661
ISIN	INE331C01025
Face value	₹1.0
Incorporated	–
Website	–
Plants (India / abroad)	–

Data built 2026-10-23 from BSE company filings (inline XBRL: Integrated Filing - Finance) + BSE results summary for earlier years; price = BSE close 2026-10-26.